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ABSTRACT
Introduction: Severe hypoglycemic events
(SHEs) are associated with significant
morbidity, mortality and costs. However, the
more common non-severe hypoglycemic events
(NSHEs) are less well explored. We investigated
the association between reported frequency of
NSHEs and SHEs among patients with type 1
diabetes mellitus (T1DM) and type 2 diabetes
mellitus (T2DM) in the PREDICTIVE study.
Methods: PREDICTIVE was a global,
prospective, observational study. Patients with
T1DM (n = 7,420) or T2DM (n = 12,981),
starting treatment with insulin detemir,
reported the number of NSHEs and SHEs
experienced during the 4 weeks prior to
baseline and follow-up visits (mean
14.4 weeks). Logistic regression was used to
determine the odds ratio (OR) of
experiencing C1 SHE, in patients having 1–4
or C5 NSHEs, versus those having 0 NSHEs,
while controlling for baseline covariates.
Results: Hypoglycemia rates were lower at
follow-up than baseline. At baseline 59.2%
(T1DM) and 18.8% (T2DM) reported any
hypoglycemia and at follow-up 39.5% (T1DM)
and 8.6% (T2DM). There was a significant
(P\0.0001) increase in the odds of C1 SHEs
with increasing frequency of NSHEs in T1DM
and T2DM, for both crude and adjusted
estimates. At baseline, in T1DM, ORs for C1
SHE were 1.92 and 2.13 for 1–4 and C5 NSHEs,
respectively; the corresponding ORs in T2DM
were 10.83 and 15.36, respectively. At follow-
up, the ORs for C1 SHE were 2.01 and 3.20
(T1DM) and 18.99 and 24.29 (T2DM) for 1–4
and C5 NSHEs, respectively.
Trial Registration Clinicaltrials.gov #NCT00659295.
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Conclusion: A statistically significant
association between NSHE and SHE frequency
was found in T1DM and T2DM. These data
provide a clear rationale for the reduction of
hypoglycemic events, regardless of severity,
while striving for optimal glycemic control.
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INTRODUCTION
Hypoglycemic events are of major clinical
importance, adversely affecting health,
quality of life, adherence to therapy and
workplace productivity [1–6]. They represent
a significant clinical concern and source of
distress in patients with both type 1 diabetes
mellitus (T1DM) and type 2 diabetes mellitus
(T2DM) [7–11], both for insulin users as well
as for patients using only oral antidiabetic
drugs (OADs) [12–15]. Hypoglycemic events or
fear of such events has been identified as the
major treatment-limiting factors in titrating
insulin to optimal glycemic targets in T2DM
[16, 17]. A recent meta-analysis of 13
randomized trials suggested that the harm
associated with severe hypoglycemic events
(SHEs) could even negate the benefit of
intensive glucose reduction [18]. Emergency
hospitalizations arising from SHEs represent a
considerable economic cost to patients and
insurers [19–21]. Despite the clinical
consequences of hypoglycemia and the
burden it causes to patients and health-care
providers, in one large (n = 3,827) European
survey, 65% of people with T1DM and 50–59%
of people with T2DM who experienced a non-
severe hypoglycemic event (NSHE) rarely or
never informed their physician about
hypoglycemia; additionally, among all
responders, 17% of those with T1DM and
21–28% with T2DM reported not being asked
about hypoglycemia by their physician during
routine appointments [22]. Clinically, there
may be an impression that the lower
frequency of hypoglycemia in T2DM means
that it is of lesser clinical importance in that
type of diabetes; such an interpretation,
however, may not adequately characterize the
impact of hypoglycemia in T2DM [8, 9, 23].
Given this background, understanding the
constellation of factors predisposing to
hypoglycemia, and SHEs in particular, is of
considerable clinical importance [24]. One of
the most consistently reported risk factors for
SHEs is a history of prior SHEs [7]. For example,
in one observational study of 267 patients with
insulin-treated diabetes, statistically significant
predictors of hypoglycemia in T1DM included a
history of previous hypoglycemia (P = 0.006)
and co-prescribing of any oral medication
(P = 0.048) [7]. For T2DM, a history of
previous hypoglycemia (P = 0.0001) and
duration of insulin treatment (P = 0.014) were
significant. NSHEs, for which third-party
assistance is not required, occur far more
commonly than SHEs; however, the clinical
and economic relevance of such events may be
underappreciated, especially in T2DM. In
particular, there is a lack of data reflecting the
potential association between NSHEs and SHEs.
The aim of this study was to report data on
the co-occurrence of NSHEs and SHEs (without
inferring a causal relationship between the
two) and, using a regression model, to
determine which covariates influence the
likelihood of experiencing a SHE.
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METHODS
Subjects
PREDICTIVE was a global, prospective, open-
label, observational study of more than 20,000
patients with T1DM or T2DM intended to
evaluate the safety and efficacy of insulin
detemir in routine clinical practice; details of
the study design and primary results have been
published [25–27]. This secondary analysis
reports data on the frequency of NSHEs and
SHEs, along with their co-occurrence, in
insulin-treated patients with T1DM (n = 7,420)
or T2DM (n = 12,981) from 11 countries
(Austria, Czech Republic, Denmark, Finland,
Germany, Ireland, Israel, Netherlands, Sweden,
Turkey, and the UK). We selected PREDICTIVE
(Clinicaltrials.gov #NCT00659295) for this
analysis because it was unique in the
systematic way in which NSHEs were recorded
and the trial enrolled sufficient numbers of
patients to allow analysis of SHEs in people with
T2DM. As an observational study, we also
believed PREDICTIVE offered the advantage of
reflecting real-world practice. The analysis in
this article does not involve any new studies of
human or animal subjects performed by any of
the authors.
Insulin Treatment
Patients entering this study were prescribed
insulin detemir (100 U/ml formulation) by
their physician as part of routine clinical care
and followed up for a mean period of
14.4 weeks. Patients currently using insulin
detemir were ineligible. 75% of patients with
T1DM were using a basal-bolus regimen at
baseline, compared with 25% of those with
T2DM. A further 31% of patients with T2DM
were using insulin plus OADs and 27% used
OADs without insulin. Neutral protamine
Hagedorn insulin was the most commonly
used basal insulin prior to entering the study
(63% T1DM, 66% T2DM), followed by insulin
glargine (34% T1DM, 29% T2DM). All decisions
about insulin dose, frequency of dosing and
other treatments were at the discretion of the
patient’s physician.
Hypoglycemic Events
Patients reported the number of NSHEs and
SHEs experienced during the 4 weeks prior to
baseline and during a 4-week period prior to
the end of their follow-up visit. SHEs were
defined as an episode with symptoms of
neuroglycopenia, in which the patient was
unable to treat himself/herself and third-party
intervention was needed, and where the patient
had one of the following characteristics:
(i) blood glucose \2.8 mmol/L (\50 mg/dL) or
(ii) reversal of symptoms after food
intake, glucagon or intravenous glucose
administration. Confirmed hypoglycemic
events where third-party assistance was not
required were classified as NSHEs. SHEs were
categorized into 0 versus C1 in frequency, and
NSHEs were classified as 0, 1–4, and C5 in
frequency, during the two reporting periods.
Statistical Analysis
Demographic variables and baseline diabetes
characteristics were summarized with
descriptive statistics. Hypoglycemic events
were analyzed by severity and frequency
(NSHEs: 0, 1–4, C5 events; SHEs: 0 and C1
event). The primary end point of this study
was the association between NSHEs and SHEs at
baseline and between NSHEs and SHEs at
follow-up. Cross-tabulations and the Chi-
square test were used to test for statistically
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significant associations between frequencies of
NSHE and SHE, for T1DM and T2DM.
Unadjusted and adjusted odds ratios (ORs) and
95% confidence intervals (CIs) for
experiencing C1 SHEs, in patients having 1–4
and C5 NSHEs versus those with 0 NSHEs, were
estimated using multivariate logistic regression
so that the effect of potential covariates could
be taken into account. Covariates for adjusted
ORs included age, body mass index (BMI),
duration of diabetes, baseline glycosylated
hemoglobin (HbA1c) and gender, which are all
potential confounders of the relationship
between NSHEs and SHEs. Data were stratified
by type of diabetes for all analyses. All analyses
were performed using SAS 9.3 Software (SAS
Institute Inc., Cary, NC, USA).
RESULTS
Patients
Baseline demographics (mean ± SD) of the
study population are summarized in Table 1.
Glycemic control at baseline was similar for
both T1DM and T2DM (HbA1c 8.2 ± 1.6 and
8.5 ± 1.6%, respectively). Glycemic control
significantly improved at follow-up which has
previously been reported [25]. As might be
expected, patients with T1DM were younger
and had a longer duration of diabetes and a
lower BMI than those with T2DM.
Frequency of Hypoglycemic Events
The proportion of patients providing data
concerning the frequency of hypoglycemic
events was high ([90%) at baseline (n = 7,399/
7,420 and n = 12,966/12,981, for T1DM and
T2DM, respectively) and at follow-up
(n = 6,837/7,420 and 12,368/12,981, for T1DM
and T2DM, respectively). Hypoglycemic
episodes per patient year have been reported
previously [25]. As might be expected, both
during the 4-week reporting periods at baseline
and at follow-up, a greater proportion of
patients with T1DM reported a hypoglycemic
event (baseline: T1DM, 4,380/7,399, 59.2%;
T2DM 2,443/12,966, 18.8%; follow-up: T1DM,
2,702/6,837, 39.5%; T2DM, 1,062/12,368,
8.6%). As these data show, the frequency of all
hypoglycemic events decreased in both T1DM
and T2DM from baseline to follow-up.
With respect to SHEs, the number of patients
experiencing SHEs was about threefold greater
in T1DM compared with T2DM at baseline
(baseline: T1DM, 741/7,399, 10.0%; T2DM,
445/12,966, 3.4%; follow-up: T1DM,
145/6,837, 2.1%; T2DM, 41/12,368, 0.3%).
When stratified by the number of NSHEs
(0, 1–4, C5 NSHEs; Fig. 1), the frequency of
SHEs was greater among patients who also
reported having NSHEs.
Association Between NSHEs and SHEs
at Baseline
At baseline, there was a statistically significant
association between the frequency of NSHEs
and SHEs, both for patients with T1DM
(P\0.0001) and for those with T2DM
(P\0.0001). For patients with T1DM, those
who experienced NSHEs had more than twice
the odds of experiencing C1 SHE, compared
with those who experienced 0 NSHEs:
unadjusted ORs [95% CIs] were 2.07 [1.72;
2.49] for 1–4 NSHEs, and 2.31 [1.90; 2.82]
for C5 NSHE. By comparison, for patients with
T2DM, the odds of experiencing C1 SHE
were[10–15 times greater for those who
experienced an NSHE, compared to those who
did not experience an NSHE in the 4 weeks prior
to the study (OR = 11.09 [8.91; 13.81] for 1–4
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NSHEs, and OR = 15.36 [11.47; 20.57] for C5
NSHEs).
In the multiple logistic regression model,
which was adjusted for gender, age, BMI, HbA1c,
and diabetes duration, NSHEs were still
consistent predictors of SHEs in both T1DM
and T2DM. Several covariates had a statistically
significant effect on the parameter estimates
Table 1 Baseline characteristics of participants in the PREDICTIVE study
Characteristic Patients with type 1 diabetes N5 7,420 Patients with type 2 diabetes N5 12,981
Gender
Female (n, %) 3,733 (50.3) 6,877 (53.0)
Male (n, %) 3,684 (49.7) 6,101 (47.0)
Missing (n, %) 3 (0.04) 3 (0.02)
Age, years 41.4 ± 16.8 60.6 ± 10.8
B55 years (n, %) 5,759 (77.6) 4,061 (31.3)
[55–65 years (n, %) 1,006 (13.6) 4,500 (34.7)
[65 years (n, %) 645 (8.7) 4,383 (33.8)
Missing (n, %) 10 (0.1) 37 (0.3)
Diabetes duration, years 16.4 ± 12.5 11.2 ± 7.5
0–5 years (n, %) 1,628 (21.9) 2,972 (22.9)
[5–10 years (n, %) 1,253 (16.9) 4,153 (32.0)
[10–20 years (n, %) 2,119 (28.6) 4,443 (34.2)
[20 years (n, %) 2,320 (31.3) 1,292 (10.0)
Missing (n, %) 100 (1.4) 121 (0.9)
Body mass index, kg/m2 25.2 ± 4.5 30.9 ± 5.9
B25 kg/m2 (n, %) 3,917 (52.8) 1,602 (12.3)
[25–30 kg/m2 (n, %) 2,469 (33.3) 4,772 (36.8)
[30–35 kg/m2 (n, %) 738 (10.0) 3,813 (29.4)
[35 kg/m2 (n, %) 200 (2.7) 2,657 (20.5)
Missing (n, %) 96 (1.3) 137 (1.1)
Baseline HbA1c, % 8.2 ± 1.6 8.5 ± 1.6
B7.5 (n, %) 2,483 (33.5) 3,289 (25.3)
[7.5–8.0 (n, %) 995 (13.4) 1,782 (13.7)
[8.0–9.0 (n, %) 1,707 (23.0) 3,203 (24.7)
[9.0 (n, %) 1,886 (25.4) 3,698 (28.5)
Missing (n, %) 349 (4.7) 1,009 (7.8)
Data are mean ± SD, unless otherwise indicated
HbA1c glycosylated hemoglobin
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(Fig. 2). For T1DM, greater BMI was associated
with slightly decreased odds of SHEs
(P = 0.0341), and longer duration of diabetes
was associated with increased odds of SHEs
(P\0.0001). For T2DM, increasing BMI was
associated with significantly lower odds of
SHEs (P = 0.0017). However, adjustment for
potential confounding using these covariates
had a negligible effect on the parameter
estimates for odds of C1 SHE in patients with
T1DM or T2DM compared to the unadjusted
estimates.
Association Between NSHEs and SHEs
at Follow-up
At follow-up, after a mean of 14.4 weeks of
therapy using insulin detemir, there was a
statistically significant association between the
frequency of NSHEs and the occurrence of SHEs,
both for patients with T1DM (P\0.0001) and
those with T2DM (P\0.0001). For patients with
T1DM, those who experienced NSHEs had[2
times the odds of also experiencing a SHE,
compared with those who experienced 0 NSHEs
(OR = 2.21 [1.51; 3.22] for 1–4 NSHEs vs. 0
NSHEs, and OR = 3.78 [2.47; 5.80] for C5 NSHE
vs. 0 NSHEs [values are unadjusted ORs and 95%
CIs]). For patients with T2DM, the odds of
experiencing a SHE were[15–20 times greater
for those who experienced an NSHE, compared
to those who did not experience an NSHE
(OR = 16.65 (8.66; 32.02) for 1–4 NSHEs vs. 0
NSHEs, and OR = 21.74 [7.17; 65.91] for C5
NSHE vs. 0 NSHEs).
Finally, 9% of T1DM and 3% of T2DM
patients who experienced a SHE at baseline
also experienced an event at follow-up. In
contrast 1% (T1DM) and 0.2% (T2DM)
experienced a SHE at follow-up without
experiencing a SHE at baseline.
In the multiple logistic regression model,
longer duration of diabetes was associated with
an increased risk of SHEs (P = 0.004) in T1DM,
whereas in T2DM, none of the covariates in the
adjusted model were statistically significant.
The odds of experiencing a SHE with
increasing frequency of NSHEs remained
statistically significant (P\0.0001) and
increased slightly in magnitude when adjusted
for confounders, for either T1DM or T2DM
(Fig. 3). In T1DM, adjusted ORs for experiencing
a SHE again changed very little compared to
unadjusted estimates (Fig. 3). However, in
T2DM, the association between NSHEs and
SHEs was further strengthened, compared to
unadjusted estimates, after adjusting for
potential confounders (Fig. 2).
DISCUSSION
These observational data, from a large cohort of
patients with T1DM or T2DM in 11 countries
(PREDICTIVE study) using insulin detemir in a
Fig. 1 Hypoglycemic events recorded during 4 weeks
before baseline and 4 weeks before follow-up, for type 1
and type 2 diabetes mellitus, in the PREDICTIVE study.
NSHE non-severe hypoglycemic event, SHE severe hypo-
glycemic event
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setting of routine care provide confirmation of a
strong association between the occurrence of
NSHEs and SHEs. Importantly, the odds of
experiencing C1 SHE increased with increasing
frequency of NSHEs (i.e., 0, 1–4 and C5 events),
both at baseline and at follow-up. This supports
the notion that NSHEs could predispose to
SHEs, a concept that is supported by the
Fig. 2 Adjusted odds ratio estimates for experiencing C1
SHEs for T1DM (top) and T2DM (bottom), at baseline in
the PREDICTIVE study. P values are for the covariate
named on the left. BMI body mass index, CI conﬁdence
interval, HbA1c glycosylated hemoglobin, NSHE non-severe
hypoglycemic event, SHE severe hypoglycemic event,
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes
mellitus
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relationship between NSHEs and SHEs being
maintained despite adjustment for potential
confounders, both in patients with T1DM and
T2DM.
As previously reported for the PREDICTIVE
study, the absolute frequency of NSHEs and
SHEs all decreased significantly from baseline
(P\0.0001) [25]. Despite this decrease in
Fig. 3 Adjusted odds ratio estimates for experiencing C1
SHEs for T1DM (top) and T2DM (bottom), at follow-up
in the PREDICTIVE study. P values are for the covariate
named on the left. BMI body mass index, CI conﬁdence
interval, HbA1c glycosylated hemoglobin, NSHE non-severe
hypoglycemic event, SHE severe hypoglycemic event,
T1DM type 1 diabetes mellitus, T2DM type 2 diabetes
mellitus
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frequency of hypoglycemic events following
treatment with insulin detemir, the
association between the frequency of NSHEs
and SHEs in this secondary analysis remained
statistically significant. Because of the very high
level of reporting ([90%) and collection of data
over a comparatively short period of time (4-
week periods), reporting fatigue should have
been minimized. Although the odds of
experiencing a SHE in subjects with NSHEs
were actually higher at follow-up, it is likely
that with fewer patients experiencing
hypoglycemia, events were concentrated
within the most vulnerable individuals, with
the association between NSHEs and SHEs
thereby becoming even stronger. Interestingly,
the advantage of T2DM with respect to having
lower frequency of SHEs (compared to T1DM)
was tempered once any NSHE was reported.
An interesting finding was that the effect of
increasing frequency of NSHEs on odds of
having C1 SHEs was much greater in T2DM
than in T1DM, being at least fivefold greater at
baseline and more than eightfold greater at
follow-up. The odds of C1 SHE were increased
from 10- to 25-fold for patients with T2DM who
reported NSHEs, whereas the odds of C1 SHE
increased only about 2- to 3-fold for patients
with T1DM who reported NSHEs (Figs. 2, 3).
This further highlights the relevance of
hypoglycemia in T2DM, which, as others have
noted [8], may be underappreciated and
highlights the need to adopt strategies
directed toward the reduction of both severe
and non-severe hypoglycemia in patients with
both T1DM and T2DM. Furthermore, our
analysis indicates that overweight people with
T2DM (BMI[35 kg/m2) seemed to have a lower
frequency of both NSHE and SHE which can be
explained by increasing insulin resistance.
Potential mechanisms that may account for
the association between NSHEs and SHEs
observed in our analysis may relate to the
effect of recurrent symptomatic hypoglycemia
with respect to blunted subsequent counter-
regulatory hormone secretion [28]. Our data
may also reflect an extension of observations
from the Action In Diabetes And Vascular
Disease: Preterax And Diamicron Modified
Release Controlled Evaluation (ADVANCE;
ClinicalTrials.gov #NCT00145925) study [15],
suggesting a clustering of hypoglycemia in
susceptible individuals.
This study supports other data evaluating the
relevance of non-severe hypoglycemia. Indeed,
NSHEs have a significant detrimental effect on
patients’ quality of life, adherence to prescribed
insulin doses and workplace productivity [1].
This was recently demonstrated from a survey of
people with diabetes in the USA, UK, Germany
and France, where over a 1-month period, mean
losses in workplace productivity were estimated
to range from $US15.26–93.47 in relation to
each NSHE. The cost of hospital treatment of a
SHE is considerably greater. In one study of 639
patients in Germany, Spain and the UK, costs
per SHE averaged $US304–693 per event [20].
Limitations
Data concerning the incidence of either NSHEs
or SHEs in this study must be interpreted with
the understanding that hypoglycemic events
were only reported during a 4-week period at
baseline and a 4-week period at the end of the
study. Due to the study design, it is not possible
to determine whether increased frequency of
NSHEs precedes the occurrence of SHEs and
whether a causal relationship exists. It is thus
possible that our observations represent an
indication bias translating into a clustering of
hypoglycemia episodes in people predisposed to
those events. To address such a consideration, it
would be interesting to investigate the temporal
Diabetes Ther (2014) 5:447–458 455
relationship between NSHEs and SHEs. It is also
possible that unrecorded clinical or socio-
demographic factors that influence the risk of
overall hypoglycemia could potentially bias the
results of this analysis. However, it should be
noted that in this study, we did measure and
control for factors that have been reported
elsewhere as important confounding variables
[7]. Another potential confounding factor in
this analysis is the influence of reporting bias,
since the data rely on patient-reported
hypoglycemic events. Self-monitored blood
glucose values were not available for any
patients with NSHEs. Thus, it is possible that
some of these patients may have had blood
glucose\2.8 mmol/L. However, in this study,
the key distinguishing factor between SHEs and
NSHEs was the requirement for assistance by a
third party. Finally, at follow-up all patients
were treated with insulin detemir which could
influence the generalizability of the association
found in this study.
The number of SHEs was too small to allow
stratification and analysis according to the
baseline regimen in T2DM. However, the
diversity of baseline regimens is reflective of
routine clinical practice, thus perhaps
increasing the generalizability of our results.
Logistic regression (dichotomous outcome and
hence ORs) were used instead of Poisson
regression (counts) for several reasons. Very
few patients had[1 SHE, and the time period
was the same for all patients and comparatively
short; therefore a Poisson model was not
appropriate and results would have been very
similar to modeling a dichotomous outcome.
The total number of SHEs may not have been
determined precisely. For these reasons, we
focused our analysis on whether or not C1
SHE occurred and did not attempt to model
the number of SHEs. Since there is a
considerable degree of variability in the
definition of hypoglycemia, combined with
the observation that the definition of SHEs
versus NSHEs is not always explicit or clear
between studies [5], future studies with a
consistent definition of hypoglycemia are
required to further explain the relationship
between NSHEs and SHEs.
CONCLUSION
NSHEs appear to be an important factor
consistently and independently associated
with the risk of SHEs among patients with
both T1DM and T2DM. The magnitude of this
risk association was more pronounced for
patients with T2DM, highlighting the
importance of non-severe hypoglycemia
both in patients with T1DM and T2DM.
Regardless of whether NSHEs are a prelude
to, or simply a marker for, SHEs (which in the
worst case may be fatal), it is essential that
physicians obtain an accurate account of their
patients’ hypoglycemic experience during
consultations. These results thus provide
both clinical and economic rationale for
making every effort to reduce the frequency
of hypoglycemic events, regardless of severity,
in patients with T1DM or T2DM.
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